Dr. Debra Patt Discusses the Paradigm Shift of Treating HER2-Low Breast Cancer
The HER2-low classification offers new treatment options for advanced breast cancer patients previously labeled as HER2-negative.
Care Advancements
American Journal of Managed Care
July 19, 2022
Previously, patients with low expression of HER2 were categorized as HER2-negative, but adding the HER2-low classification creates new opportunities for patients with advanced breast cancer, explained Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology.
